Migraine; StatusNCT04429048
Effect of Acupressure in Migraine: Single-blinded, Randomized, Controlled Clinical Trial
A study testing Acupressure elastic band (Sea-Band) and General elastic band (no bud) in people with Migraine; Status, run by National Taiwan University Hospital at 1 site in Taiwan.
Trial summary
Background : Migraine is one of the most complex, prevalent, debilitating neurologic disorder in the world. In clinical experience, there are limitation over western medicine for migraine, especially some extra adverse effects. Read more about this study
- Who is it for?
- Ages 20 to 50 years
- Conditions the study is for
- Migraine; Status
- What is being tested?
- Acupressure elastic band (Sea-Band) and General elastic band (no bud)
- Type of treatment
- Medical device
- Could I receive a placebo?
- Yes, some participants may receive a placebo
- How many people
- 17 participants
- Where
- 1 siteTaiwan
- Study dates
- 4 Jul 2020to 8 Jul 2021
- Phase
- Interventional
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 20 to 50 years
- All sexes
- No healthy volunteers
- Adult
- Inclusion criteria
- Age ranged from 20 to 50-year-old (inclusion)
- Female or male.
- Neurological examination was within normal limit.
- Neither epileptiform discharge from EEG nor abnormality of neuroimage
- Exclusion criteria
- Headache was results from adverse effects for NSAIDs and Propranolol.
- Active skin lesion or oozing wound over PC6 acupoints.
- Pregnancy or lactation.
- Recent traumatic brain injury or brain tumor.
- Secondary headache
- Brain surgical history.
- Refuse sign informed consent.
- Extremely abnormal metabolic disturbance (such as iron deficiency anemia, hypo/hypernatremia, hypo/hyperkalemia, hypo/hypercalcemia, hypo/ hypermagnesemia) and liver/renal dysfunction ALT > 3x normal upper limits; creatinine >1.4)
Trial locations and contacts
1 site in 1 country.
Taiwan1 site
National Taiwan University Hospital Yunlin Branch
Douliu, Yunlin County, 64041
About this study
Official title: Effect of Acupressure at PC6 on Headache in Patients With Migraine: Single-blinded, Randomized, Controlled Clinical Trial
Background :
Migraine is one of the most complex, prevalent, debilitating neurologic disorder in the world. In clinical experience, there are limitation over western medicine for migraine, especially some extra adverse effects. In traditional Chinese medicine(TCM), there are some reviews and clinical practice point out acupressure at PC6 could relieve nausea/ vomiting and pain while migraine. Recent researches also mention Calcitonin gene-related peptide (CGRP) and Neurokinin A (NKA) in some degree correlated with the mechanism of migraine.
Read more
Objective:
CGRP and NKA play vital roles of migraine. In comparison with oral medication only and PC6 acupressure via oral medication, if there were better effect for migraine control. In addition, investigators evaluate the plasma CGRP and NKA level before and after study to figure out if any positive value and any correlation with acupressure.
Method:
By single-blinded, randomized, controlled clinical trial, total of 56 patients with migraine were divided equally into acupressure group (modern routing standard therapy plus PC6 acupressure) and control group (modern routing standard therapy). Before intervention, the participants needed to finish the Migraine Disability Assessment (MIDAS) questionnaire evaluation. After 6 weeks, investigators will evaluate the severity, frequencies of headaches and pain-killer consumption as primary outcome. In addition, investigators will investigate if there were change of serum CGRP/NKA level after 6 weeks and the score changes of MOS 36-Item Short-Form Health Survey as secondary outcome.
Expected results:
The investigators predict that PC6 acupressure may not only reduce severity, frequencies and duration of headaches but also reduce the dose of NSAIDs. In addition, the PC6 acupressure also may reduce levels of serum CGRP and NKA, and improve the quality of life meanwhile.
Read the detailed description
Introduction:
Migraine is one of the most complex, prevalent, debilitating neurologic disorder and the prevalence higher in female group. In general, there are many kinds of therapy for migraine nowadays including of acute abortion oral drugs such as triptan, ergotamine, non-steroid anti-inflammatory drugs, acetaminophen and preventive agents such as calcium channel blocker (Flunarizine), anti-epileptic drugs (valproic acid, Topiramate, Pregabalin), beta adrenergic-blocker (Propranolol), Selective Serotonin Reuptake Inhibitors(SSRI), anti-emetic agents (Prochlorperazine) and other injection therapy such as Onabotulinum Toxin A or CGRP (Calcitonin gene-related peptide) antagonist etc. The CGRP plays an important role of trigemino-vascular responses in migraine. The serum CGRP levels elevated while migraine attack and chronic migraine, therefore, CGRP is a potential biomarker. In recent studies, higher plasma CGRP level during interictal phase of migraine or chronic migraine is indicated the better response for Onabotulinum Toxin A and reduced plasma CGRP level can relieve the discomfort of migraine. Neurokinin A (NKA) levels of venous blood are significantly higher in responders than these nonresponse before the rizatriptan treatment, whereas reduced the levels of both CGRP and NKA one hours after the treatment . The headache is associated with nausea in about 80% of episodes, vomiting in about 30% in patients with migraine.
PC6 is belong to pericardium meridian locates the anterior aspect of forearm between the tendons of the palmaris longus and the flexor carpi radialis, 2 cun proximal to the wrist transverse stripes just on the median nerve . The antiemetic is lower for preventing postoperative nausea and vomiting in the combination PC6 acupoint stimulation than these patients with antiemetic only. Acupuncture at the PC6 is an effective alternative treatment to conventional pharmacological treatment and resulted in almost immediate cessation of intraoperative nausea and vomiting. Therefore, acupressure at PC6 is an effective and safety method for nausea and vomiting. In addition, stimulation at PC6 can activate hypothalamic orexin neurons, and that release orexins to induce analgesia. Taken together, PC6 stimulation can produce effect of both analgesia and antiemetic effects. The present study suppose stimulation at PC6 is beneficial for the treatment of migraine.
Therefore, the investigators designed a single-blinded, randomized, controlled trial to evaluate the effect of acupressure at PC6 on headache in patients with migraine.
Method and study design:
(A) Participants The patients with migraine were enrolled from the outdoor patients (OPD) of neurological department, Yunlin branch of National Taiwan University hospital. The basic laboratory data including peripheral blood cells, Na/K/Ca/Mg, alanine aminotransferase (ALT), creatinine, iron/total iron-binding capacity (TIBC)/ferritin to exclude extremely abnormal metabolic disturbance or liver/renal functional impairment which may cause secondary headache; and the awake electroencephalography (EEG) and brain image including computer tomography (C-T) or magnetic resonance image (MRI) also were done to rule out any intracranial structure lesion prior to the trial.
The migraine was diagnosed according to clinical manifestation and criteria from beta version of the third edition of the International Classification of Headache Disorders (ICHD-3). In addition, non-steroid anti-inflammatory drugs (NSAIDs) are used as episodic way while migraine attack and Propranolol (Inderal R) is used as preventive way no matter when migraine attack. In addition, the participants needed to finish the Migraine Disability Assessment (MIDAS) questionnaire evaluation of 6 weeks.
(B) Study design: Single-blinded, randomized, controlled clinical trial. (C) Assessment time: before PC6 acupressure (V1), two weeks after acupressure (V2), four weeks after acupressure (V3) and six weeks after acupressure (D) Statistical analysis : Categorical data will be displayed in numbers and percentages, whereas continuous variables will be given as means ± standard deviations or median (Q1, Q3). Differences in categorical variables will be tested using the chi-square test or Fisher exact test and differences in continuous variables will be tested using the two sample independent t test or Mann-Whitney test between groups. The generalized estimating equations (GEE) will be used to compare the change of primary outcomes over time (the four time points (V1-V4)) between two groups. A p value of less than 0.05 will be considered statistically significant. All statistical analyses will be performed using SPSS Statistics 24or R version 3.4.4 .
Outcome :
The study of the present study predicts that PC6 acupressure may reduce severity of headaches, the frequency of headache attacks and duration of headache, and also reduce the dose of NSAID. In addition, the PC6 acupressure also may reduce levels of serum CGRP and NKA, and also may improve the quality of life.
- Conditions
- Migraine; Status
- Being tested
- Acupressure elastic band (Sea-Band), General elastic band (no bud)
- Keywords
- migraine ,acupressure,CGRP,neurokinin A
- Medical subject headings
- Migraine Disorders
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Acupressure elastic band (Sea-Band)Device
The PC6 acupressure was done via Sea-Band in persistent compressive state for 3 minutes per time and three times a day , then at least 5 days in one week for 6 weeks continuously except modern routine standard therapy
General elastic band (no bud)Device
general elastic band was put over bilateral PC6 acupoints
| Study group | Role | What they receive |
|---|---|---|
| acupressure group | Experimental | The participants received modern routing standard therapy accompanied with the round plastic studs of sea-band were placed just on the skin surface of bilateral PC6 acupoints , and then keep the persistent compressive state for 3 minutes per time and three times a day. Receives: Device: Acupressure elastic band (Sea-Band) |
| control group | Sham comparator | The participants received modern routing standard therapy only with general elastic band without bud over PC6 acupoints. Receives: Device: General elastic band (no bud) |
What is being measured
The primary outcome is the main question the study is designed to answer.
Headache duration
duration (if attack less than 4hours which means better response)
Measured: After 6 weeks , evaluate how many episodes of lesser duration(<4hours) of the two groups
Headache severity
Severity by visual analog scale (0~10), if VAS score decreased 2 points which means better results
Measured: After 6 weeks, evaluate the headache severity (VAS score) if any decreased
Headache frequency
how many times headache occurred (if attack < 8 times which means effective)
Measured: evaluate total headache episodes after 6 weeks
dosage of pain killers
how many dosage of pain kill taken (if pain killer taken less than 20 pills which means effective therapy)
Measured: evaluation total amount of pain-killer consumption after 6 weeks
Secondary outcomes (3)
Calcitonin gene-related peptide (CGRP) level
Check serum CGRP level to evaluate the correlation
Measured: 1st time: 1 day of sign informed consent ; 2nd time: through study completion, an average of 6 weeks
Neurokinin A (NKA) level
Check NKA level to realize any discrepancy
Measured: 1st time: 1 day of sign informed consent ; 2nd time: through study completion, an average of 6 weeks
the score of 36-Item Short Form Health Survey (SF-36)
Complete form for quality evaluation (score: 0~100, worse to better)
Measured: through study completion, an average of 6 weeks
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted11 Jun 2020
- Study start4 Jul 2020
- Primary completion25 Jun 2021
- Study completion8 Jul 2021
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Migraine; StatusStudies of the same condition, open and under way.
- More trials run by National Taiwan University HospitalThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Single blind
- Who is masked
- Participant
- Enrolment
- 17 participants (actual)
Sponsor and investigators
- Lead sponsor
- National Taiwan University Hospital
- Sponsor type
- University, hospital or other
- Collaborators
- China Medical University, Taiwan
- Responsible party
- Sponsor
- Investigators
- Chih-hung Tsai, MD, Principal investigator, National Taiwan University Hospital
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT04429048
- Sponsor's protocol ID
- 202002094RIND
- Status last verified
- Jul 2022
- First submitted
- 24 May 2020
- Last updated
- 13 Jul 2022
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
Study at a glance
From the registry record, last updated by the sponsor on 13 Jul 2022. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Effect of Acupressure at PC6 on Headache in Patients With Migraine: Single-blinded, Randomized, Controlled Clinical Trial
- ClinicalTrials.gov ID
- NCT04429048
- Acronym / sponsor ID
- 202002094RIND
- Conditions
- Migraine; Status
- Keywords
- migraine ,acupressure,CGRP,neurokinin A
- Study type
- Interventional
- Recruitment status
- Completed
- Enrolment
- 17 participants (actual)
- Lead sponsor
- National Taiwan University HospitalUniversity, hospital or other
- Collaborators
- China Medical University, Taiwan
- Study start
- 4 Jul 2020 (actual)
- Primary completion
- 25 Jun 2021 (actual)
- Study completion
- 8 Jul 2021 (actual)
- First posted
- 11 Jun 2020 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
Background :
Migraine is one of the most complex, prevalent, debilitating neurologic disorder in the world. In clinical experience, there are limitation over western medicine for migraine, especially some extra adverse effects. In traditional Chinese medicine(TCM), there are some reviews and clinical practice point out acupressure at PC6 could relieve nausea/ vomiting and pain while migraine. Recent researches also mention Calcitonin gene-related peptide (CGRP) and Neurokinin A (NKA) in some degree correlated with the mechanism of migraine.
Objective:
CGRP and NKA play vital roles of migraine. In comparison with oral medication only and PC6 acupressure via oral medication, if there were better effect for migraine control. In addition, investigators evaluate the plasma CGRP and NKA level before and after study to figure out if any positive value and any correlation with acupressure.
Method:
By single-blinded, randomized, controlled clinical trial, total of 56 patients with migraine were divided equally into acupressure group (modern routing standard therapy plus PC6 acupressure) and control group (modern routing standard therapy). Before intervention, the participants needed to finish the Migraine Disability Assessment (MIDAS) questionnaire evaluation. After 6 weeks, investigators will evaluate the severity, frequencies of headaches and pain-killer consumption as primary outcome. In addition, investigators will investigate if there were change of serum CGRP/NKA level after 6 weeks and the score changes of MOS 36-Item Short-Form Health Survey as secondary outcome.
Expected results:
The investigators predict that PC6 acupressure may not only reduce severity, frequencies and duration of headaches but also reduce the dose of NSAIDs. In addition, the PC6 acupressure also may reduce levels of serum CGRP and NKA, and improve the quality of life meanwhile.
Detailed description
Introduction:
Migraine is one of the most complex, prevalent, debilitating neurologic disorder and the prevalence higher in female group. In general, there are many kinds of therapy for migraine nowadays including of acute abortion oral drugs such as triptan, ergotamine, non-steroid anti-inflammatory drugs, acetaminophen and preventive agents such as calcium channel blocker (Flunarizine), anti-epileptic drugs (valproic acid, Topiramate, Pregabalin), beta adrenergic-blocker (Propranolol), Selective Serotonin Reuptake Inhibitors(SSRI), anti-emetic agents (Prochlorperazine) and other injection therapy such as Onabotulinum Toxin A or CGRP (Calcitonin gene-related peptide) antagonist etc. The CGRP plays an important role of trigemino-vascular responses in migraine. The serum CGRP levels elevated while migraine attack and chronic migraine, therefore, CGRP is a potential biomarker. In recent studies, higher plasma CGRP level during interictal phase of migraine or chronic migraine is indicated the better response for Onabotulinum Toxin A and reduced plasma CGRP level can relieve the discomfort of migraine. Neurokinin A (NKA) levels of venous blood are significantly higher in responders than these nonresponse before the rizatriptan treatment, whereas reduced the levels of both CGRP and NKA one hours after the treatment . The headache is associated with nausea in about 80% of episodes, vomiting in about 30% in patients with migraine.
PC6 is belong to pericardium meridian locates the anterior aspect of forearm between the tendons of the palmaris longus and the flexor carpi radialis, 2 cun proximal to the wrist transverse stripes just on the median nerve . The antiemetic is lower for preventing postoperative nausea and vomiting in the combination PC6 acupoint stimulation than these patients with antiemetic only. Acupuncture at the PC6 is an effective alternative treatment to conventional pharmacological treatment and resulted in almost immediate cessation of intraoperative nausea and vomiting. Therefore, acupressure at PC6 is an effective and safety method for nausea and vomiting. In addition, stimulation at PC6 can activate hypothalamic orexin neurons, and that release orexins to induce analgesia. Taken together, PC6 stimulation can produce effect of both analgesia and antiemetic effects. The present study suppose stimulation at PC6 is beneficial for the treatment of migraine.
Therefore, the investigators designed a single-blinded, randomized, controlled trial to evaluate the effect of acupressure at PC6 on headache in patients with migraine.
Method and study design:
(A) Participants The patients with migraine were enrolled from the outdoor patients (OPD) of neurological department, Yunlin branch of National Taiwan University hospital. The basic laboratory data including peripheral blood cells, Na/K/Ca/Mg, alanine aminotransferase (ALT), creatinine, iron/total iron-binding capacity (TIBC)/ferritin to exclude extremely abnormal metabolic disturbance or liver/renal functional impairment which may cause secondary headache; and the awake electroencephalography (EEG) and brain image including computer tomography (C-T) or magnetic resonance image (MRI) also were done to rule out any intracranial structure lesion prior to the trial.
The migraine was diagnosed according to clinical manifestation and criteria from beta version of the third edition of the International Classification of Headache Disorders (ICHD-3). In addition, non-steroid anti-inflammatory drugs (NSAIDs) are used as episodic way while migraine attack and Propranolol (Inderal R) is used as preventive way no matter when migraine attack. In addition, the participants needed to finish the Migraine Disability Assessment (MIDAS) questionnaire evaluation of 6 weeks.
(B) Study design: Single-blinded, randomized, controlled clinical trial. (C) Assessment time: before PC6 acupressure (V1), two weeks after acupressure (V2), four weeks after acupressure (V3) and six weeks after acupressure (D) Statistical analysis : Categorical data will be displayed in numbers and percentages, whereas continuous variables will be given as means ± standard deviations or median (Q1, Q3). Differences in categorical variables will be tested using the chi-square test or Fisher exact test and differences in continuous variables will be tested using the two sample independent t test or Mann-Whitney test between groups. The generalized estimating equations (GEE) will be used to compare the change of primary outcomes over time (the four time points (V1-V4)) between two groups. A p value of less than 0.05 will be considered statistically significant. All statistical analyses will be performed using SPSS Statistics 24or R version 3.4.4 .
Outcome :
The study of the present study predicts that PC6 acupressure may reduce severity of headaches, the frequency of headache attacks and duration of headache, and also reduce the dose of NSAID. In addition, the PC6 acupressure also may reduce levels of serum CGRP and NKA, and also may improve the quality of life.
Study design
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Single blind (participant)
- Number of arms
- 2
| Arm | Type | Receives |
|---|---|---|
| acupressure group | Experimental | Device: Acupressure elastic band (Sea-Band)The participants received modern routing standard therapy accompanied with the round plastic studs of sea-band were placed just on the skin surface of bilateral PC6 acupoints , and then keep the persistent compressive state for 3 minutes per time and three times a day. |
| control group | Sham comparator | Device: General elastic band (no bud)The participants received modern routing standard therapy only with general elastic band without bud over PC6 acupoints. |
Who may qualify
- Ages
- 20 to 50 years
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Acupressure elastic band (Sea-Band)The PC6 acupressure was done via Sea-Band in persistent compressive state for 3 minutes per time and three times a day , then at least 5 days in one week for 6 weeks continuously except modern routine standard therapy | Device | acupressure group |
| General elastic band (no bud)general elastic band was put over bilateral PC6 acupoints | Device | control group |
Primary outcome
Headache duration
Time frame: After 6 weeks , evaluate how many episodes of lesser duration(<4hours) of the two groups
duration (if attack less than 4hours which means better response)
Headache severity
Time frame: After 6 weeks, evaluate the headache severity (VAS score) if any decreased
Severity by visual analog scale (0~10), if VAS score decreased 2 points which means better results
Headache frequency
Time frame: evaluate total headache episodes after 6 weeks
how many times headache occurred (if attack < 8 times which means effective)
dosage of pain killers
Time frame: evaluation total amount of pain-killer consumption after 6 weeks
how many dosage of pain kill taken (if pain killer taken less than 20 pills which means effective therapy)
3 secondary outcomes
Calcitonin gene-related peptide (CGRP) level
Time frame: 1st time: 1 day of sign informed consent ; 2nd time: through study completion, an average of 6 weeks
Neurokinin A (NKA) level
Time frame: 1st time: 1 day of sign informed consent ; 2nd time: through study completion, an average of 6 weeks
the score of 36-Item Short Form Health Survey (SF-36)
Time frame: through study completion, an average of 6 weeks
Results and safety
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 13 Jul 2022.
Related trials for Migraine; Status
Recruiting
Basic Body Awareness Therapy in Individuals With Migraine
Migraine
RecruitingObservational study
CGRP Inhibition, Autonomic Function, and Migraine
Episodic Migraine, Chronic Migraine
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Chih-hung Tsai, MD principal investigator
National Taiwan University Hospital
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A study testing Acupressure elastic band (Sea-Band) and General elastic band (no bud) in people with Migraine; Status, run by National Taiwan University Hospital at 1 site in Taiwan.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 13 Jul 2022. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in Taiwan. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. Some participants in this study may receive a placebo. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Headache duration (time frame: After 6 weeks , evaluate how many episodes of lesser duration(<4hours) of the two groups). The study lists 4 primary outcomes in all. It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 13 Jul 2022.